Apixaban for Extended Treatment of Venous Thromboembolism

20121,326 citationsJournal Articlebronze Open Access

Authors

Giancarlo Agnelli · University of Perugia

Harry R. Büller · McMaster University

Alexander T. Cohen · King's College Hospital

Madelyn Curto · Pfizer (United States)

Alexander Gallus · Flinders University

Margot Johnson · Pfizer (United States)

Anthony R. Porcari ·

Abstract

Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 8, pp. 699-708

DOI: 10.1056/nejmoa1207541

Field-Weighted Citation Impact: 69.32